The U.S. Food and Drug Administration has introduced a proposal to limit the availability of active ingredients like semaglutide and tirzepatide for use in compounded medications. These ingredients are commonly used in treatments for obesity and diabetes, and their inclusion on the bulk drug list has enabled compounding pharmacies to produce customized versions of these drugs. The FDA's move aims to strengthen medication safety, ensure consistent quality, and reduce risks associated with unregulated compounding practices. By potentially removing these substances from the list, the agency would restrict their use to approved pharmaceutical manufacturers.
This shift comes as demand for weight-loss and diabetes medications continues to rise, prompting widespread use of compounded formulations. The proposal could significantly affect patient access, especially in regions where branded drugs are less available or more expensive. It also raises concerns among compounding pharmacies about their long-term viability. The FDA’s initiative underscores a broader push to standardize drug sourcing and improve supply chain reliability, though it may trigger debate over balancing regulation with patient needs.